Boston Scientific reports positive data from Synergy stent trial

Boston Scientific has announced positive data from its Evolve clinical programme, which supports the benefits of its Synergy bioabsorbable polymer stent system.

The everolimus-eluting bioabsorbable polymer platinum chromium coronary stent system met its primary endpoint in this non-inferiority study, which evaluated the one-year rate of target lesion failure. It marked the first successful US pivotal trial of the device.

With 1,684 patients enrolled at 125 sites worldwide, the study is comparing the performance of the new device to the established Promus Element stent. Data from this study will support the firm's application for US and Japanese regulatory approval of the product.

Kevin Ballinger, president of interventional cardiology at Boston Scientific, said: "The Evolve II Trial adds to our growing body of knowledge about the promising Synergy Bioabsorbable Polymer Stent, which is designed to provide early healing and freedom from long-term polymer exposure."

This comes after the company recently scored the highest rating of 100 percent in the Human Rights Campaign Foundation's 2015 Corporate Equality Index, thanks to its commitment to lesbian, gay, bisexual and transgender equality in the workplace.